EIF3H and neoplasm: In addition, the administration of the combination of LGK974 and trametinib in EIF3H-high group significantly decreased Ki67-positive tumor cells and protein levels of p-ERK and c-Myc, while the impact on EIF3H-low group was less effective (Fig. 7e, f).